Arbutus Biopharma Corp(ABUS)

$5.18▲0.21 (4.23%)

Chart

Arbutus Biopharma Corp(ABUS)

NASDAQ

$5.18▲0.21 (4.23%)

Chart Studio

ABUS(ABUS)

ABUS

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.02

Aug 5, 2026 · Reports before open

Revenue Estimate

$700,000

FY2026E EPS$0.75

FY2029E EPS$0.34

Analyst Sentiment

Wall St. Consensus

Buy

10 analysts·Moderate coverage

Score

8 Buy (80%)2 Hold (20%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

880%

Hold

220%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$8.50

+64.1%

Consensus

$8.50

+64.1%

Bull

$8.50

+64.1%

12-Month Target Range10 analysts

$8.50$8.50$8.50

Current $5.18Consensus

Current Price

$5.18

Upside to Consensus

$3.32

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-98.51%

EPS—

FY2028

Rev+1972.11%

EPS—

FY2029

Rev+210.17%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E
Revenue Avg	$181M	$3M	$56M	$174M
Low	$181M	$3M	$56M	$174M
High	$181M	$3M	$56M	$174M
EBITDA Avg	$-181M	$-3M	$-56M	$-174M
Low	$-181M	$-3M	$-56M	$-174M
High	$-181M	$-3M	$-56M	$-174M
EBIT Avg	$-181M	$-3M	$-56M	$-174M
Low	$-181M	$-3M	$-56M	$-174M
High	$-181M	$-3M	$-56M	$-174M
Net Income Avg	$144M	$-17M	$-27M	$65M
Low	$144M	$-17M	$-27M	$65M
High	$144M	$-17M	$-27M	$65M
EPS Avg	$0.75	$-0.09	$-0.14	$0.34
Low	$0.75	$-0.09	$-0.14	$0.34
High	$0.75	$-0.09	$-0.14	$0.34
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$681,000	$681,000	$681,000	$681,000	$681,000	$681,000
Low	$681,000	$681,000	$681,000	$681,000	$681,000	$681,000
High	$681,000	$681,000	$681,000	$681,000	$681,000	$681,000
EBITDA Avg	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000
Low	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000
High	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000
EBIT Avg	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000
Low	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000
High	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000	$-681,000
Net Income Avg	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M
Low	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M
High	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M
EPS Avg	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02
Low	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02
High	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02	$-0.02
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Mar 17, 2022H.C. Wainwright

Arbutus Biopharma (ABUS) Stock: $8.50 Price Target And Buy Rating

Target:$8.50

+181.5%from $3.02

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance